Ensysce Biosciences to Showcase Extended Release Nafamostat Formulation for Prescription Drug Overdose Protection at AAPS 2023 PharmSci 360 Event
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences (NASDAQ:ENSC) announced that Dr. Dolly Jacob from Quotient Sciences will present their collaborative work on an extended release nafamostat formulation for prescription drug overdose protection at the AAPS 2023 PharmSci 360 event. The presentation will feature the development of Ensysce's PF614-MPAR for severe pain treatment, designed to prevent abuse and overdose.
October 18, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ensysce Biosciences will present their work on a drug designed to prevent prescription drug overdose at a major pharmaceutical event. This could potentially increase visibility and interest in the company's products.
The presentation at a major pharmaceutical event could increase visibility for Ensysce Biosciences and its products. This could potentially lead to increased interest from investors and a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100